Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, Blumenthal R, Danesh J, Smith GD, Demets D, Evans S, Law M, McMahon S, Martin S, Neal B, Poulter N, Preiss D, Ridker P, Roberts I, Rodgers A, Sandercok P, Schulz K, Sever P, Simes J, Smeeth L, Wald N, Yusuf S, Peto R. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016;388:2532-61. [Ref.ID 100988]

Reith C, Landray M, Devereaux PJ, Bosch J, Granger CB, Baigent C, Califf RM, Collins R, Yusuf S. Randomized clinical trials - Removing unnecessary obstacles. N Engl J Med 2013;369:1061-5. [Ref.ID 96099]

Vollset SE, Clarke R, Lewington S, Ebbing M, Halsey J, Lonn E, Armitage J, Manson JE, Hankey GJ, Spence JD, Galan P, Bonaa KH, Jamison R, Gaziano JM, Guarino P, Baron JA, Logan RF, Giovannucci EL, den Heijer M, Ueland PM, Bennett D, Collins R, Peto R, for the B-Vitamin Treatment Trialists' Collaboration. Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50 000 individuals. Lancet 2013;381:1029-36. [Ref.ID 95120]

Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Alencar VHM, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou M-F, Inbar M, Khaled H, Kielanowska J, Kwan W-H, Mathew BS, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R, for the Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013;381:805-16. [Ref.ID 95085]

Bulbulia R, Armitage J, Collins R. Safety of long-term simvastatin discontinuation. Authors' reply. Lancet 2012;370:1704. [Ref.ID 92879]

Clarke R, Bennett DA, Parish S, Verhoef P, Dötsch-Klerk M, Lathrop M, Xu P, Nordestgaard BG, Holm H, Hopewell JC, Saleheen D, Tanaka T, Anand SS, Chambers JC, Kleber ME, Ouwehand WH, Yamada Y, Elbers C, Peters B, Stweart AFR, Reilly MM, Thorand B, Yusuf S, Engert JC, Assimes TL, Kooner J, Danesh J, Watkins H, Samani NJ, Collins R, Peto R, for the MTHFR Studies Collaborative Group. Homocysteine and coronary heart disease: meta-analysis of MTHFR case-control studies, avoiding publication bias. PLOS Medicine 2012:febrero. [Ref.ID 92301]

Emberson J, Bennett D, Parish S, Armitage J, Collins R, on behalf of the Heart Protection Study Collaborative Group. C-reactive protein in the Heart Protection Study. Authors' reply. Lancet 2011;377:1918-9. [Ref.ID 91291]

Clarke R, Halsey J, Lewington S, Lonn E, Armitage J, Manson JE, Bonaa KH, Spence JD, Nygard O, Jamison R, Gaziano JM, Guarino P, Bennett D, Mir F, Peto R, Collins R, for the B-Vitamin Treatment Trialists' Collaboration. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality. Arch Intern Med 2010;170:1622-30. [Ref.ID 89480]

Baigent C, Blackwell L, Emberson J, Collins R, Peto R, on behalf of the Antithrombotic Trialists' Collaboration. Aspirin in the primary prevention of vascular disease. ATT secretariat's reply. Lancet 2009;374:879. [Ref.ID 86689]

Collins R, Peto R. Analyses of cancer data from three ezetimibe trials. The authors reply. N Engl J Med 2009;360:87. [Ref.ID 84940]

Peto R, Emberson J, Landray M, Baigent C, Collins R, Clare R, Califf R. Analyses of cancer data from three ezetimibe trials. N Engl J Med 2008;359:1357-66. [Ref.ID 84067]

Kearney PM, Keech A, Simes J, Collins R, Baigent C, on behalf of the Cholesterol Treatment Trialists' (CTT) Collaboration. Statins and diabetes. Authors' reply. Lancet 2008;371:1752. [Ref.ID 82975]

Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Collins R, for the PSC collaborators. Cholesterol, statins, and mortality. Authors' reply. Lancet 2008;371:1162-3. [Ref.ID 82575]

Davies C, Collins R. Balancing potential risks and benefits of using confidential data. BMJ 2006;333:349-51. [Ref.ID 77848]

Chen Z, Collins R, Peto R, on behalf of the COMMIT/CCS-2 collaboration. COMMIT/CCS-2 studies. Lancet 2006;368:642-3. [Ref.ID 77826]

Chen Z, Collins R, Peto R, Xie J, Jiang L, Liu L. Clopidogrel and metoprolol in myocardial infarction. Autors' reply. Lancet 2006;367:813. [Ref.ID 76464]

Baigent C, Keech A, Kearney P, Collins R, Simes J, on behalf of the Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of cholesterol-lowering treatment. Authors' reply. Lancet 2006;367:470-1. [Ref.ID 76163]

Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjedsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Östergren J, for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906. [Ref.ID 74795]

Fairbank J, Frost H, Wilson-Macdonald J, Yu LM, Barker K, Collins R, for the Spine Stabilisation Trial Group. Randomised controlled trial to compare surgical stabilisation of the lumpar spine with an intensive rehabilitation programme for patients with chronic low back pain: the MRC spine stabilisation trial. BMJ 2005;330:1233-9. [Ref.ID 73971]

Wheeler J, Keavney B, Watkins H, Collins R, Danesh J. Paraoxonase polymorphisms and coronary heart disease. Authors' reply. Lancet 2004;364:580. [Ref.ID 71001]